GlassScriptPhysician profile
David J Maron
NPI 1538251962
$21,718.32
in general payments reported to CMS, 2019-2025
11 companies · $13K in 2025
The $13K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $7,893 · 2024: $793 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $3,037 · Travel and Lodging: $350 · Education: $52.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,279.00 |
| Food and Beverage | $3,036.87 |
| Travel and Lodging | $349.97 |
| Education | $52.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $6,600.00 | 2025 | |
| Bayer Healthcare LLC | $3,504.70 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $3,313.40 | 2023-2024 | |
| Cleerly, INC. | $2,972.74 | 2023 | |
| Abiomed | $2,750.00 | 2025 | |
| Scilex Pharmaceuticals INC. | $2,400.00 | 2023 | Gloperba |
| Merck Sharp & Dohme LLC | $125.00 | 2025 | |
| Idorsia Pharmaceuticals US INC | $52.48 | 2025 | Tryvio |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,889.83 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Maron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.